Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06409130 · ClinicalTrials.gov registry record · Phase 2
Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease
A Phase 2 study of Alcohol-related Liver Disease, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT06409130 is a Phase 2 study of Alcohol-related Liver Disease that has completed, run by Novo Nordisk A/S. The registered enrollment target is 270 participants, above the 202-participant average among 3 other Alcohol-related Liver Disease trials with a reported enrollment target (34% higher). The trial reports 20 study locations across 12 states.
The verdict
NCT06409130, a Phase 2 study of Alcohol-related Liver Disease, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment participants get is decided by chance. The study will last for about 39 weeks.
Conditions Studied
Interventions
- DRUG Semaglutide
- DRUG NNC0194-0499
- DRUG NNC0194-0499 placebo
- DRUG Semaglutide placebo (Group A)
- DRUG Cagrilintide + semaglutide
Study Locations (20)
Florida
- Covenant Metabolic Specialists LLC - Fort Myers
- Miguel Rebollar PA - Hialeah
- UF Hlth Jacksonville - Jacksonville
- Univ of Miami/Schiff Ctr - Miami
- Covenant Metabolic Specialists LLC - University Park
Arizona
- The Institute for Liver Health - Chandler
- Arizona Liver Center - Tucson
- Del Sol Research Management, LLC - Tucson
California
- OM Research LLC - Lancaster
- California Liver Research Institute - Pasadena
Pennsylvania
- University of Pennsylvania Hospital - Philadelphia
- UPMC_Center for Liver Care - Pittsburgh
Illinois
- Rush University Med. Cntr - Chicago
Kansas
- Kansas Medical Clinic, PA - Topeka
Louisiana
- Louisiana Research Center, LLC - Shreveport
Massachusetts
- Boston Medical Center_Cary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2024-05-20 |
| Est. Completion | 2026-01-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06409130
The ClinicalTrials.gov registry entry for NCT06409130 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 202-participant average among 3 other Alcohol-related Liver Disease trials with a reported enrollment target (34% higher). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Alcohol-related Liver Disease appearing as the primary indexed condition, and to 5 interventions - of which Semaglutide is the first listed.
NCT06409130 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT06409130 about?
NCT06409130 is a clinical study titled "Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease". The study will look at the effects of NNC0194-0499, cagrilintide and semaglutide, on liver damage and alcohol use in participants with alcoholic liver disease. Participants will get NNC0194-0499, semaglutide, cagrilintide or ''dummy" medicine in different treatment combinations. Which treatment part...
What is the current status of trial NCT06409130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2024-05-20. Estimated completion is 2026-01-12.
What conditions does trial NCT06409130 study?
This clinical trial studies the following conditions: Alcohol-related Liver Disease.
What interventions are being tested in trial NCT06409130?
The interventions under investigation include: Semaglutide (DRUG), NNC0194-0499 (DRUG), NNC0194-0499 placebo (DRUG), Semaglutide placebo (Group A) (DRUG), Cagrilintide + semaglutide (DRUG).
Who is sponsoring clinical trial NCT06409130?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06409130 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Illinois, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alcohol-related Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
Implementation of Mobile-based Programs for Alcohol Cessation in Treatment of Alcohol-associated Liver Disease
RECRUITING · NA
-
Investigating HepQuant DuO Test as a Biomarker in Alcohol-related Liver Disease
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.